Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned an average rating of “Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $206.67.

A number of analysts have recently weighed in on the company. Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, Chardan Capital reissued a “buy” rating and set a $212.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of KRYS. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech during the third quarter worth about $40,000. Values First Advisors Inc. purchased a new stake in shares of Krystal Biotech in the 3rd quarter valued at about $53,000. GAMMA Investing LLC boosted its position in shares of Krystal Biotech by 184.8% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock valued at $78,000 after purchasing an additional 279 shares during the period. Huntington National Bank grew its stake in Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after buying an additional 283 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after buying an additional 412 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $154.81 on Friday. The company has a market cap of $4.45 billion, a P/E ratio of 87.46 and a beta of 0.85. The stock has a 50-day moving average of $167.93 and a two-hundred day moving average of $181.11. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.67) earnings per share. On average, analysts anticipate that Krystal Biotech will post 3.03 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).